Kidney Week

Abstract: TH-PO611

Longitudinal Analysis of 100 Biopsy-Confirmed Focal Segmental Glomerulosclerosis: Incidence and Treatment Outcomes of a 10-Year, Single-Center Experience in Saudi Arabia

Session Information

• Membranous Nephropathy, FSGS, and Minimal Change Disease
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Al Dalbhi, Sultan, Prince Sultan Military Medical City, Riyadh, Riyadh, Saudi Arabia

Sultan Al Dalbhi, MBBS

• Alotaibi, Asma Mohammed, Prince Sultan Military Medical City, Riyadh, Riyadh, Saudi Arabia

Asma Mohammed Alotaibi, MBBS, FNP

• Alotaibi, Manal Eidhah Q., Umm Al-Qura University, Makkah, Makkah, Saudi Arabia

Manal Eidhah Q. Alotaibi, MBBS, FASN

Background

This study analyzes trends in biopsy-confirmed Focal Segmental Glomerulosclerosis (FSGS) over a ten-year period and evaluates outcomes of various treatment protocols and amins to identify factors influencing disease progression and disease prognosis.

Methods

A retrospective study of 100 biopsy-confirmed FSGS cases from 2013 to 2022 were analyzed. Hypothetical individual patient data were generated for treatment response, renal function, proteinuria, and quality of life. Statistical methods included trend analysis, survival analysis, and comparative analysis.

Results

The incidence rate of FSGS showed variability over the years, ranging from 2.86% to 21.67%. Notably, the highest incidence rate was observed in 2016 (21.67%). Immunosuppressive therapy and supportive care had higher complete remission rates (33.33% and 48.39%, respectively) compared to steroids (16.67%). All treatment groups experienced a decline in eGFR, with steroids showing the highest mean decline (-14.85 mL/min/1.73 m). Proteinuria reduction was most significant with steroids (-1.83 g/g). Quality of life scores were highest for patients on steroids (mean: 72.64).

Conclusion

This study emphasizes the necessity of individualized treatment strategies for FSGS and highlights the significance of long-term monitoring of patient outcomes.